Immunic/IMUX

$1.45

-1.7%
-
1D1W1MYTD1YMAX

About Immunic

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Ticker

IMUX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Duane Nash

Employees

77

Headquarters

New york, United States
Website
imux.com

Immunic Metrics

BasicAdvanced
$131.75M
Market cap
-
P/E ratio
-$2.11
EPS
2.08
Beta
-
Dividend rate

What the Analysts think about Immunic

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
719.31% upside
High $28.00
Low $4.00
$1.45
Current price
$11.88
Average price target

Immunic Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-21.5M
-5.29%
Profit margin
0%
-

Immunic Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.48%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.58
-$0.54
-$0.51
-$0.48
-
Expected
-$0.52
-$0.52
-$0.55
-$0.51
-$0.26
Surprise
11.86%
3.05%
-6.85%
-6.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Immunic stock

Buy or sell Immunic stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing